Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04069299 · ClinicalTrials.gov registry record
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
A clinical trial of Neuroendocrine Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT04069299: Active study of Neuroendocrine Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT04069299 is a study of Neuroendocrine Carcinoma that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 30 participants, below the 279-participant average among 13 other Neuroendocrine Carcinoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04069299, a study of Neuroendocrine Carcinoma, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to understand the extent and degree of somatostatin receptor expression in poorly differentiated neuroendocrine carcinomas . This may help to make a determination if a radiolabeled somatostatin analog therapy, also referred to as peptide receptor radiotherapy (PRRT), can be a potential alternative in the future. At this time, radiolabeled somatostatin analogs have not been tested in patients with poorly differentiated neuroendocrine carcinomas, and their efficacy in this disease is not well known Understanding the extent and degree of somatostatin receptor expression is important in order to evaluate the potential of radiolabeled somatostatin analog therapy for treatment of poorly differentiated neuroendocrine carcinomas.
Primary Outcome
Percentage of participants with uniformly positive 68Ga-dotatate PET (positivity defined as SUV uptake \> liver for all tumors at least 1cm in size). Note: Standard Uptake Value (SUV) is used to determine activity in PET imaging.
Conditions Studied
Interventions
- DRUG 68Ga-DOTATATE
- DIAGNOSTIC_TEST Positron Emission Tomography (PET) Scan
Study Locations (1)
Florida
- H Lee Moffitt Cancer & Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-09-25 |
| Est. Completion | 2026-01 |
What the registry record for NCT04069299 still lists
NCT04069299 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 279-participant average among 13 other Neuroendocrine Carcinoma trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Neuroendocrine Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which 68Ga-DOTATATE is the first listed.
NCT04069299 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04069299 about?
NCT04069299 is a clinical study titled "Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract". The purpose of the study is to understand the extent and degree of somatostatin receptor expression in poorly differentiated neuroendocrine carcinomas . This may help to make a determination if a radiolabeled somatostatin analog therapy, also referred to as peptide receptor radiotherapy (PRRT), can ...
What is the current status of trial NCT04069299?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2019-09-25. Estimated completion is 2026-01.
What conditions does trial NCT04069299 study?
This clinical trial studies the following conditions: Neuroendocrine Carcinoma.
What interventions are being tested in trial NCT04069299?
The interventions under investigation include: 68Ga-DOTATATE (DRUG), Positron Emission Tomography (PET) Scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04069299?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04069299 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04069299's enrollment target sits among peer trials
30 13th of 13 higher than 1 of 13 other Neuroendocrine Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
RECRUITING · Phase 2
-
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
ACTIVE NOT RECRUITING · Phase 2
-
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI